Taivex’s anti-cancer oral drug T-1301 received Phase I IND approval by the US FDA to enter clinical development

Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1301 on June 17, 2021, to initiate phase I clinical trial for the treatment of advanced solid tumors. T-1301 is a small molecular oral anti-cancer drug licensed from National Health Research Institutes in 2019. After completion of pre-clinical safety evaluation, as well as chemistry, …

Taivex’s anti-cancer oral drug T-1301 received Phase I IND approval by the US FDA to enter clinical development Read More »